Dr. Parkinson has been ESSA’s President and Chief Executive Officer since 2016 and has been a member of ESSA’s Board of Directors since 2015. Dr. Parkinson has more than 30 years of experience in clinical oncology development. Prior to joining ESSA, Dr. Parkinson was a Venture Partner at New Enterprise Associates, Inc. and served as the President and CEO of Nodality, Inc., a biotechnology company developing human cell-based translational diagnostic tools. Throughout his career, Dr. Parkinson has held senior roles in clinical oncology development at a number of pharmaceutical and biotech companies, including Biogen, Amgen and Novartis, and has overseen the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix. Dr. Parkinson currently serves as Director on the Boards of CTI Biopharma, Inc. and Angiocrine Bioscience Inc. Dr. Parkinson received his M.D. from the University of Toronto, has previously held academic positions at Tufts and the University of Texas MD Anderson Cancer Center, and has served as Chief of the Investigational Drug Branch and acting Associate Director of the Cancer Therapy Evaluation Program of the National Cancer Institute. He has authored over 100 peer-reviewed publications and is a recipient of the FDA’s Cody Medal.

• 

  President in ESSA Pharmaceuticals

  Developing the Next Generation of Treatments for Prostate Cancer

• 

  Chief Executive Officer (CEO) in ESSA Pharmaceuticals

  Developing the Next Generation of Treatments for Prostate Cancer

• 

  Director in ESSA Pharmaceuticals

  Developing the Next Generation of Treatments for Prostate Cancer